In treating GBM, the previously reported AMPK/Sp1/ATM pathway and the FDX1-mediated DNA-PKcs/Akt regulatory mechanism may serve as a promising selective target to overcome radioresistance under severe hypoxia. This evidence concerns the gene FDX1 and glioblastoma.